830 related articles for article (PubMed ID: 32003505)
1. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.
Hu B; Lin JZ; Yang XB; Sang XT
Cell Prolif; 2020 Mar; 53(3):e12772. PubMed ID: 32003505
[TBL] [Abstract][Full Text] [Related]
2. Therapeutically targeting essential metabolites to improve immunometabolism manipulation after liver transplantation for hepatocellular carcinoma.
Zhang W; Zhao Y; He Q; Lang R
Front Immunol; 2023; 14():1211126. PubMed ID: 37492564
[TBL] [Abstract][Full Text] [Related]
3. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
4. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
5. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.
Liu L; Zhang R; Deng J; Dai X; Zhu X; Fu Q; Zhang H; Tong Z; Zhao P; Fang W; Zheng Y; Bao X
Cancer Immunol Immunother; 2022 Jan; 71(1):121-136. PubMed ID: 34028567
[TBL] [Abstract][Full Text] [Related]
6. RIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis.
Wu L; Zhang X; Zheng L; Zhao H; Yan G; Zhang Q; Zhou Y; Lei J; Zhang J; Wang J; Xin R; Jiang L; Peng J; Chen Q; Lam SM; Shui G; Miao H; Li Y
Cancer Immunol Res; 2020 May; 8(5):710-721. PubMed ID: 32122992
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
8. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
Xu K; Xia P; Chen X; Ma W; Yuan Y
Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
[TBL] [Abstract][Full Text] [Related]
9. HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape.
Han Q; Zhao H; Jiang Y; Yin C; Zhang J
Cells; 2019 Jun; 8(6):. PubMed ID: 31181729
[TBL] [Abstract][Full Text] [Related]
10. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression.
Wu Q; Zhou L; Lv D; Zhu X; Tang H
J Hematol Oncol; 2019 May; 12(1):53. PubMed ID: 31142326
[TBL] [Abstract][Full Text] [Related]
11. Targeting Lipid Metabolism in Liver Cancer.
Alannan M; Fayyad-Kazan H; Trézéguet V; Merched A
Biochemistry; 2020 Oct; 59(41):3951-3964. PubMed ID: 32930581
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated fatty acid metabolism in hepatocellular carcinoma.
Wang M; Han J; Xing H; Zhang H; Li Z; Liang L; Li C; Dai S; Wu M; Shen F; Yang T
Hepat Oncol; 2016 Oct; 3(4):241-251. PubMed ID: 30191046
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in the emerging role of exosome in hepatocellular carcinoma.
Abudoureyimu M; Zhou H; Zhi Y; Wang T; Feng B; Wang R; Chu X
Cell Prolif; 2019 Mar; 52(2):e12541. PubMed ID: 30397975
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses.
Foglia B; Beltrà M; Sutti S; Cannito S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108625
[TBL] [Abstract][Full Text] [Related]
15. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment.
Liu YT; Tseng TC; Soong RS; Peng CY; Cheng YH; Huang SF; Chuang TH; Kao JH; Huang LR
J Immunother Cancer; 2018 Dec; 6(1):144. PubMed ID: 30526672
[TBL] [Abstract][Full Text] [Related]
16. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
17. CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment.
Wan X; Cheng C; Shao Q; Lin Z; Lu S; Chen Y
Tumour Biol; 2016 May; 37(5):6073-84. PubMed ID: 26608371
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Lu C; Rong D; Zhang B; Zheng W; Wang X; Chen Z; Tang W
Mol Cancer; 2019 Aug; 18(1):130. PubMed ID: 31464625
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.
Ma C; Zhang Q; Greten TF
FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485
[TBL] [Abstract][Full Text] [Related]
20. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.
Rodríguez MM; Fiore E; Bayo J; Atorrasagasti C; García M; Onorato A; Domínguez L; Malvicini M; Mazzolini G
Mol Ther; 2018 Dec; 26(12):2738-2750. PubMed ID: 30301668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
